Cellectis (CLLS) Net Income towards Common Stockholders (2015 - 2026)
Cellectis (CLLS) posted quarterly Net Income towards Common Stockholders of -$0.18 for Q1 2026, little changed year-over-year from -$0.18 in Q1 2025, and up 30.77% quarter-over-quarter from -$0.26 in Q4 2025.
Powered by 
Analysis
Cellectis (CLLS) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
Cellectis' Net Income towards Common Stockholders history runs 12 years deep, the most recent figure standing at -$0.18 for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders changed 0.0% year-over-year to -$0.18; the TTM figure through Mar 2026 stood at -$23.1 million (up 45.41% YoY), while the FY2025 annual figure was -$0.67, up 100.0% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$0.18, up from -$0.26 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $5.9 million in Q4 2024, with the low at -$41.8 million in Q4 2023.
- The 5-year median for Net Income towards Common Stockholders is -$18.9 million (2022), against an average of -$15.7 million.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders tumbled 168.88% in 2022, then jumped 118.76% in 2024.
- Cellectis' Net Income towards Common Stockholders stood at -$26.8 million in 2022, then plunged by 55.86% to -$41.8 million in 2023, then surged by 114.17% to $5.9 million in 2024, then sank by 100.0% to -$0.26 in 2025, then soared by 30.77% to -$0.18 in 2026.
- Business Quant data shows CLLS's Net Income towards Common Stockholders at -$0.18 in Q1 2026, -$0.26 in Q4 2025, and $589000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -15.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.75 Mn |
| Mar 31, 2026 | -18.00 Mn |
| Dec 31, 2025 | -260.00 |
| Sep 30, 2025 | 589,000.00 |
| Jun 30, 2025 | -23.74 Mn |
| Mar 31, 2025 | -18.00 Mn |
| Dec 31, 2024 | 5.92 Mn |
| Sep 30, 2024 | -23.06 Mn |
| Jun 30, 2024 | -25.27 Mn |
| Mar 31, 2024 | 5.64 Mn |
| Dec 31, 2023 | -41.80 Mn |
| Sep 30, 2023 | -17.48 Mn |
| Jun 30, 2023 | -11.71 Mn |
| Mar 31, 2023 | -30.07 Mn |
| Dec 31, 2022 | -26.82 Mn |
| Sep 30, 2022 | -28.47 Mn |
| Jun 30, 2022 | -18.95 Mn |
| Mar 31, 2022 | -31.91 Mn |
| Dec 31, 2021 | -25.00 Mn |
| Sep 30, 2021 | -37.41 Mn |